Document is current
Any future updates will be listed below
-
Authors
Walewska, Alicja
Tynecka, Marlena
Ksiezak, Sylwia
Tarasik, Agnieszka
Janucik, Adrian
Bondarczuk, Kinga
Rusak, Malgorzata
Dabrowska, Milena
Hady, Hady Razak
Radziwon, Piotr
Sredzinski, Dariusz
Reszec-Gielazyn, Joanna
Moniuszko, Marcin
Eljaszewicz, Andrzej https://orcid.org/0000-0002-8980-1474
-
Funding
Funding for this research was provided by:
Uniwersytet Medyczny w Bialymstoku (Subsidy Founds, Subsidy Founds)
Fundacja na rzecz Nauki Polskiej (START)
- License Information
-
More Information
Article History
Received: 9 March 2025
Accepted: 7 July 2025
First Online: 22 July 2025
Change Date: 12 September 2025
Change Type: Update
Change Details: The original article has been updated to re-implement an omitted ESM.
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from Ethics Committee of the Medical University of Bialystok (for Buffy Coat Collection Approval No: R-I-002/634/2018 approved 28 February 2019 entitled: “Assessment of human acellular dermal matrices and cellular therapies in diabetic wound healing efficacy”, for MSC collection Approval No: APK.002.114.2021 from 25.02.2021 entitled: Utilization of Mesenchymal Stem Cells, Fibroblasts, and Acellular Scaffolds Based on Human Skin Derived from Dermal-Fat Folds in Experimental Models). All animal experiments were approved by the Local Ethical Committee in Olsztyn (Approval No: number 35/2019 from 26 April 2019, entitled: Application of Human Adipose-Derived Mesenchymal Stem Cells (hADMSCs) in the Control of House Dust Mite (HDM)-Induced Allergic Lung Inflammation). The work has been reported in line with the ARRIVE guidelines 2.0.
: All authors have read and approved the final version of this manuscript. The authors confirm that the manuscript represents original work and has not been published or submitted elsewhere, in whole or in part.
: MT reports National Science Centre (grant no. 2020/37/N/NZ5/04144); MM reports earlier personal payments from Astra Zeneca, GSK, Sanofi, Berlin-Chemie/Menarini, Chiesi, Lek-AM, Takeda, Teva, Novartis, CSL Behring, Celon, and support for attending meetings from Chiesi, Astra Zeneca, GSK, Berlin-Chemie/Menarini. AE reports National Science Centre (grant no. 2020/37/N/NZ5/04144), National Centre for Research and Development (POLTUR3/MT-REMOD/2/2019). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors read and accepted the manuscript.
